Cefixime

Analytical Profiles of Drug Substances and Excipients

Volumn 25, Issue C, 1998, Pages 39-83

  Okeke, Claudia C ^a   Srinivasan, V Srini ^a   Brittain, Harry G ^b  

^a UNITED STATES PHARMACOPEIA   (United States)

^b Acute Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548472778     PISSN: 10756280     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0099-5428(08)60752-2     Document Type: Article

References (30)

1. M. Nishida and Y. Shigi, "The Role of Permeability and Affinity for Penicillin Binding Proteins in the Antibacterial Activity of the Third-Generation Cephalosporins", in New Beta-Lactam Antibiotics: A Review from Chemistry to Clinical Efficacy of the New Cephalosporins. H. C. Neu, ed., College of Physicians of Philadelphia, Philadelphia, 1982, pp 65-81.
2. Y. Shigi, Y. Matsumoto, M. Kaizu, Y. Fijishita, and H. Kojo, J. Antibiotics, 37, 790(1984).
3. K. Kawabata, H. Yamanaka, H. Takasugi, and T. Takaya, J. Antibiotics, 39, 404(1986).
4. Drugs of the Future, 8, 682(1983);
5. Drugs of the Future, 9, 628(1984).
6. (a) H. Sakamoto, T. Hirose, and Y. Mine, Y. J. Antibiotics, 38, 496(1985);
7. (b) H. Sakamoto, T. Hirose, and S. Nakamoto, Y. J. Antibiotics, 1088(1985).
8. K. Kawabata, H. Yamanaka, H. Takasugi, and T. Takaya, Chem. Pharm. Bull, 34, 3458(1986).
9. (a) H. Yamanaka, T. Chiba, K. Kawabata, H. Takasugi, T. Masugi, and T. Takaya, J. Antibiotics, 38, 1738(1985);
10. (b) Fujisawa Pharmaceutical Co., Ltd.. Osaka, Japan, private communication.
11. K. G. Mooney, F. S. Forbes, D. Wadgoankar, W. Berger, P. Kulkarni, S. Ku, R. Ferrio, W. Hoselting, N. Rodriguez-Hornedo, and M. Cronosiza, in Cefixime: Physical and Chemical Evaluation of a Cephalosporin Trihydrate, University of Wisconsin Update Conference, April 1988.
12. S. Kitamura, A. Miyamae, S. Koda, and Y. Morimoto, Int. J. Pharm., 56, 125(1989).
13. S. Kitamura. S. Koda, A. Miyamae, T. Yasuda, and Y. Morimoto, Int. J. Pharm., 59, 217(1990).
14. Y. Namiki, T. Tanabe, T. Kobayashi, J. Tanabe, Y. Okimura, S. Koda, and Y. Morimoto, J. Pharm. Sci., 76, 208(1987).
15. Requirements for Antibiotics Products of Japan, Japan Antibiotics Research Association, 1993.
16. Cefixime, United States Pharmacopoeia 23, National Formulary 18, United States Pharmacopeial Convention, Inc. Rockville, MD. 1995. p. 293.
17. A. J. Falkowski, Z. M. Look, H. Noguchi, and B. M. Siber, J. Chrom., 422, 145(1987).
18. G. Montay, F. Masala, Y. le Roux, A. le Liboux, J. Uhlrich, D. Chassard, J. J. Thebault, G. Roche, and A. Frydman, Dings, 42 Suppl. 4, 6(1991).
19. A. Markham and R. N. Brogden, Dntg Eval., 49, 1007(1995).
20. M. Dhib, B. Moulin. A. Leroy, B. Hameau, M. Godlin, R. Johannides, and J. P. Fillastre. Eur. J. Clin. Pharmacol., 41, 579(1991).
21. F. Kees, K. G. Naber, G. Sigl, W. Ungethum, H. Grobecker, AnneimiUelforschung, 40, 293(1990).
22. R. D. Faulkner, P. Fernandez, G. Lawrence, L. L. Sia, A. J. Falkowski, A. I. Weiss, A. Yacobi, and B. M. Silber, J. Clin. Pharmacol., 28, 700(1988).
23. R. D. Faulkner, W. Bohaychuk, J. D. Haynes, R. E. Desjardins, A. Yacobi, and B. M. Silber, Eur. J. Clin. Pharmacol., 34, 525(1988).
24. R. D. Faulkner, A. Yacobi, J. S. Barone, S. A. Kaplan, and B. M. Silber, Pediatr. Infect Dis. J., 6, 963(1987).
25. A. W. Bauer, W. M. M. Kirby, and J. C. Sherris, Am. J. Clin. Pathol, 45, 493(1966).
26. Performance Standards for Antimicrobial Disk Susceptibility Tests (M2-A3), National Committee for Clinical Laboratory Standards December 1984.
27. Standardized disk susceptibility test, Federal Register, 39 (May 30), 19182(1974).
28. R. D. Faulkner, W. Bohaychuk, R. A. Lane, J. D. Haynes, R. E. Desjardins, A. Yacobi, and B. M. Silber, J. Antimicrob. Chemotherap., 21, 787(1988).
29. R. D. Faulkner, W. Bohaychuk, R. E. Desjardins, Z. M. Look, J. D. Haynes, A. I. Weiss, and B. M. Silber, J. Clin. Pharmacol., 27, 807(1987).
30. D. C. Brittain, B. E. Scully, T. Hirose, and H. C. Neu, Clin. Pharmacol Therap., 38, 590(1985).